Skip to content

US FDA Clears Terumo Blood and Cell Technologies’ New Plasma Collection Technology

Rika was developed in response to the industry’s need for technological advancement and process improvements to drive efficiency and quality while maintaining donor safety and a sufficient plasma supply.

Investing in the source plasma industry is a natural evolution in the Terumo Blood and Cell Technologies portfolio given its experience and leadership in apheresis technology. The company spends three times more than the industry average in development as an innovation partner to customers globally.

“Rika will revolutionize plasma collection center operations,” said Antoinette Gawin, President and Chief Executive Officer, Terumo Blood and Cell Technologies. “We innovated around the donor and plasma center experience, creating an entire new ecosystem. At the heart of our innovation is operational efficiency designed to collect plasma in 35 minutes or less. This will help meet the need for plasma-derived therapies. Today, as an example, it could take 130 donations to treat one patient with a primary immunodeficiency for a year.This is such an important moment for us to Contribute to Society through Healthcare and fulfill our purpose of reaching more patients.”

The new technology is focused on donor and plasma collection center employee experience. A collection time of 35 minutes or less, combined with volume of 200 milliliters or less outside the donor’s body, can mean a more comfortable donation experience. Rika’s advanced control system enhances donor safety by monitoring the process and providing alerts and visual cues that guide the operator. Rika makes automatic adjustments during each procedure, enabling a more seamless operator experience and the ability to spend more time with the donor.

Rika is part of an extensive ecosystem that integrates plasma collection technology, IT solutions, services and program support. All this is anticipated to support center productivity and efficiency to optimize plasma collections and meet the needs of patients who rely on plasma-derived therapies.

“With this crucial milestone achieved, we look forward to rolling this new technology out

to our US collection centers,” said CSL Plasma General Manager michelle meyer. “CSL Plasma’s decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice.”

About Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo Blood and Cell Technologies’ customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 130 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending.

We have global headquarters in Lakewood, Colo., USA, along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.

SOURCE Terumo Blood and Cell Technologies

.